These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 4677070)

  • 1. In vitro inhibition of dopa decarboxylase by 6-alkyl derivatives of 3-(3,4-dihydroxyphenyl)alanine (dopa).
    Morgenstern AP; Nauta WT
    Arzneimittelforschung; 1972 Oct; 22(10):1766-8. PubMed ID: 4677070
    [No Abstract]   [Full Text] [Related]  

  • 2. SUBSTRATE SPECIFICITY OF DOPA DECARBOXYLASE.
    AWAPARA J; PERRY TL; HANLY C; PECK E
    Clin Chim Acta; 1964 Sep; 10():286-9. PubMed ID: 14205921
    [No Abstract]   [Full Text] [Related]  

  • 3. Distribution of DOPA-2- 14 C in relation to DOPA-1- 14 C (carboxyl- 14 C-labelled DOPA) in mice before and after inhibition of DOPA-decarboxylase, studied by whole-body autoradiography.
    Tjälve H; Ullberg S
    Arch Int Pharmacodyn Ther; 1972 Oct; 199(2):376-88. PubMed ID: 4627124
    [No Abstract]   [Full Text] [Related]  

  • 4. Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.
    Bartholini G; Pletscher A
    J Pharmacol Exp Ther; 1968 May; 161(1):14-20. PubMed ID: 5648492
    [No Abstract]   [Full Text] [Related]  

  • 5. [Research on the inhibitory action of several salicylic chalcones on the aromatic L-aminoacid-decarboxylase].
    Lesieur-Demarquilly I; Mizon J; Osteux R
    Ann Pharm Fr; 1973 Nov; 31(11):705-8. PubMed ID: 4794659
    [No Abstract]   [Full Text] [Related]  

  • 6. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM; Parks LC; Kopin IJ
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decarboxylation of 3,4-dihydroxyphenylalanine by oxyhemoglobin.
    Yamabe H; Lovenberg W
    Biochem Biophys Res Commun; 1972 May; 47(4):733-9. PubMed ID: 5063594
    [No Abstract]   [Full Text] [Related]  

  • 8. Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase.
    Borri Voltattorni C; Bertoldi M; Bianconi S; Deng WP; Wong K; Kim I; Herbert B; Kirk KL
    Biochem Biophys Res Commun; 2002 Jul; 295(1):107-11. PubMed ID: 12083775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of L-DOPA on blood pressure and sympathetic nerve activity after decarboxylase inhibition in cats.
    Watanabe AM; Judy WV; Cardon PV
    J Pharmacol Exp Ther; 1974 Jan; 188(1):107-13. PubMed ID: 4809262
    [No Abstract]   [Full Text] [Related]  

  • 10. [On the formation of H-3-dopa from H-3-tyrosine and determination of the dopa synthesis rate in the fowl and cat adrenal gland under in vivo conditions].
    Hempel K; Männl HF
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1967; 257(4):391-408. PubMed ID: 4232726
    [No Abstract]   [Full Text] [Related]  

  • 11. DOPA DECARBOXYLASE ACTIVITY IN THE SKIN.
    MOELLER H
    Acta Derm Venereol; 1963; 43():485-90. PubMed ID: 14061560
    [No Abstract]   [Full Text] [Related]  

  • 12. CATECHOLAMINES, BIOSYNTHESIS AND INHIBITORS OF FORMATION.
    WEISS B; ROSSI GV
    Am J Pharm Sci Support Public Health; 1963 Jun; 135():206-18. PubMed ID: 14046042
    [No Abstract]   [Full Text] [Related]  

  • 13. 6-alkyl derivatives of 3-(3,4-dihydroxyphenyl)alanine (Dopa). I. Synthesis via oxazolinones.
    Morgenstern AP; Schuijt C; Nauta WT
    J Chem Soc Perkin 1; 1971; 22():3706-12. PubMed ID: 5167081
    [No Abstract]   [Full Text] [Related]  

  • 14. Decrease of the 3,4-dihydroxyphenylalanine (DOPA) decarboxylase activities in human erythrocytes and mouse tissues after administration of DOPA.
    Tate SS; Sweet R; McDowell FH; Meister A
    Proc Natl Acad Sci U S A; 1971 Sep; 68(9):2121-3. PubMed ID: 5289372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IN-VITRO DECARBOXYLATION OF NEW PHENYLALANINE DERIVATIVES.
    FERRINI R; GLAESSER A
    Biochem Pharmacol; 1964 May; 13():798-801. PubMed ID: 14181284
    [No Abstract]   [Full Text] [Related]  

  • 16. The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study.
    Foster SB; Wrona MZ; Han J; Dryhurst G
    Chem Res Toxicol; 2003 Oct; 16(10):1372-84. PubMed ID: 14565778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the activity of the enzyme DOPA decarboxylase in Musca domestica L.
    Malacrida A; Cima L; Gasperi G; Grigolo A
    Ital J Biochem; 1974 Jan; 23(1):12-8. PubMed ID: 4829141
    [No Abstract]   [Full Text] [Related]  

  • 18. Biochemical and behavioral effects of some substituted catechols.
    De Ropp RS; Kastl L; Furst A
    Arch Int Pharmacodyn Ther; 1969 Sep; 181(1):127-32. PubMed ID: 5350775
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of pyridoxal phosphate and L-dopapyridoxal phosphate on DOPA decarboxylase activity.
    Tran N
    Experientia; 1972 Sep; 28(9):1021-2. PubMed ID: 4665286
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.